A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

NCT ID: NCT05169489

Last Updated: 2025-10-21

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-24
• Study Completion Date: 2025-09-19

Brief Summary

This non-randomized, open label, multi-site, first-in-human, Phase 1/2 study CRC-403 will evaluate the safety and efficacy of bbT369 in subjects with relapsed and/or refractory B cell non-Hodgkin's lymphoma (NHL).

A long-term follow-up (LTF-01 [NCT06798298]) is planned, in which subjects who received bbT369 will be followed for up to 15 years after drug product infusion to evaluate for safety and continued efficacy.

Detailed Description

Former Sponsor 2seventy bio

The trial was intended to be a Phase 1/2 trial, but no participants were enrolled in Phase 2, consequently the study was terminated in Phase 1.

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

bbT369 Experimental Arm

Open label, single arm treatment with bbT369

Group Type: EXPERIMENTAL

bbT369

Intervention Type: BIOLOGICAL

bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene, suspended in a cryopreservative solution.

Interventions

bbT369

bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene, suspended in a cryopreservative solution.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• ≥18 years of age at the time of signing informed consent.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• Diagnosis of B-cell NHL according to WHO 2017 classification or WHO 2016 classification where applicable:

1. DLBCL (germinal center B cell [GCB] or activated B cell [ABC] type or not otherwise specified [NOS])

2. HGBCL (with MYC and BCL2 and/or BCL6 rearrangements or NOS)

3. PMBCL

4. FL 3b

5. DLBCL transformed from FL

• Participants must have relapsed or refractory (r/r) B cell NHL after autologous stem cell transplant (ASCT) or at least 2 prior lines of therapy including an anti-CD20 monoclonal antibody and an anthracycline containing chemotherapy regimen. Note: participants with DLBCL transformed from FL must have r/r disease after ASCT or at least 2 prior therapies following transformation irrespective of therapeutic agents.
• At least 1 FDG-avid lesion per Lugano Classification criteria at time of enrollment.

Exclusion Criteria

• Treatment with any investigational cellular therapy prior to enrollment. Treatment with an approved anti-CD19 CAR T cell therapy in an investigational setting may be permitted after discussion with and approval of the Sponsor.
• Progression within 6 weeks of prior anti-CD19 CAR T cell therapy.
• Residual toxicities or end-organ damage to vital organs from prior therapy that could put a subject at undue risk based on Investigator's assessment. Toxicities related to prior cytokine release syndrome (CRS) or neurotoxicity must be resolved.
• If a subject has received prior anti-CD19 CAR T therapy, development of ≥ Grade 3 CAR T related CRS or ≥ Grade 3 neurotoxicity that in the opinion of the Investigator would cause unacceptable risk of toxicity to the subject upon treatment with bbT369.
• Primary central nervous system (CNS) lymphoma or a history or presence of clinically relevant CNS pathology.
• Active autoimmune disease requiring systemic immunosuppressive and/or cytotoxic therapy within the past two years.
• Treatment with any prior anti-CD79a therapy.
• Previous history of an allogeneic bone marrow transplantation. Autologous stem cell transplantation (ASCT) is permitted.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Regeneron Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trial Management

Role: STUDY_DIRECTOR

Regeneron Pharmaceuticals

Locations

Stanford Cancer Institute

Stanford, California, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Moffitt Cancer Center

Tampa, Florida, United States

Sarah Cannon

Nashville, Tennessee, United States

Countries

United States

Other Identifiers

CRC-403

Identifier Type: -

Identifier Source: org_study_id